Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;31(5):3417-3426.
doi: 10.1007/s00330-020-07434-z. Epub 2020 Nov 4.

Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma

E Reizine  1 , M Ronot  2   3   4 , M Ghosn  5 , J Calderaro  6   7   8 , N Frulio  9 , P Bioulac-Sage  10   11 , H Trillaud  12 , V Vilgrain  2   3   4 , V Paradis  4   12 , A Luciani  5   7   8
Affiliations

Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma

E Reizine et al. Eur Radiol. 2021 May.

Abstract

Objectives: To assess the value of hepatospecific MR contrast agent uptake on hepatobiliary phase (HBP) images to detect marked activation of the β-catenin pathway in hepatocellular adenomas (HCAs).

Methods: This multicentric retrospective IRB-approved study included all patients with a pathologically proven HCA who underwent gadobenate dimeglumine-enhanced liver MRI with HBP. Tumor signal intensity on HBP was first assessed visually, and lesions were classified into three distinct groups-hypointense, isointense, or hyperintense-according to the relative signal intensity to liver. Uptake was then quantified using the lesion-to-liver contrast enhancement ratio (LLCER). Finally, the accuracy of HBP analysis in depicting marked β-catenin activation in HCA was evaluated.

Results: A total of 124 HCAs were analyzed including 12 with marked β-catenin activation (HCA B+). Visual analysis classified 94/124 (76%), 12/124 (10%), and 18/124 (14%) HCAs as being hypointense, isointense, and hyperintense on HBP, respectively. Of these, 1/94 (1%), 3/12 (25%), and 8/18 (44%) were HCA B+, respectively (p < 0.001). The LLCER of HCA B+ was higher than that of HCA without marked β-catenin activation in the entire cohort (means 4.9 ± 11.8% vs. - 19.8 ± 11.4%, respectively, p < 0.001). A positive LLCER, i.e., LLCER ≥ 0%, had 75% (95% CI 43-95%) sensitivity and 97% (95% CI 92-99%) specificity, with a LR+ of 28 (95% CI 8.8-89.6) for the diagnosis of HCA B+.

Conclusions: Hepatospecific contrast uptake on hepatobiliary phase is strongly associated with marked activation of the β-catenin pathway in hepatocellular adenoma, and its use might improve hepatocellular adenoma subtyping on MRI.

Key points: • Tumor uptake on hepatobiliary phase in both the visual and quantitative analyses had a specificity higher than 90% for the detection of marked β-catenin activation in hepatocellular adenoma. • However, the sensitivity of visual analysis alone is inferior to that of LLCER quantification on HBP due to the high number of HCAs with signal hyperintensity on HBP, especially those developed on underlying liver steatosis.

Keywords: Contrast media; Hepatocellular adenoma; Magnetic resonance imaging.

PubMed Disclaimer

References

    1. Edmondson HA, Henderson B, Benton B (1976) Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 294:470–472. https://doi.org/10.1056/NEJM197602262940904 - DOI - PubMed
    1. Nault J-C, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144:888–902. https://doi.org/10.1053/j.gastro.2013.02.032 - DOI - PubMed
    1. Belghiti J, Cauchy F, Paradis V, Vilgrain V (2014) Diagnosis and management of solid benign liver lesions. Nat Rev Gastroenterol Hepatol 11:737–749. https://doi.org/10.1038/nrgastro.2014.151 - DOI - PubMed
    1. European Association for the Study of the Liver (EASL) (2016) EASL clinical practice guidelines on the management of benign liver tumours. J Hepatol 65:386–398. https://doi.org/10.1016/j.jhep.2016.04.001 - DOI
    1. Dokmak S, Paradis V, Vilgrain V et al (2009) A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 137:1698–1705. https://doi.org/10.1053/j.gastro.2009.07.061 - DOI - PubMed

LinkOut - more resources